← Human Trials & Peer-Reviewed Studies
Immune dyscrasia in adult growth hormone deficiency: Evaluation of hemolytic complement activity (CH50) and IgG subclasses.
Plain-language guide to PMID 33152922 (2020): observational study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and GHRH (Growth Hormone-Releasing Hormone) in 38 subjects.
Key Facts
- PMID
- 33152922
- Journal
- Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
- Year
- 2020
- Study type
- Observational Study
- Authors
- Vergani E et al. (8 authors)
- DOI
- 10.1016/j.biopha.2020.110757
What This Study Did, in Plain Language
What Was Tested
This observational study looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and GHRH (Growth Hormone-Releasing Hormone).
The aim of this case-control observational study is to analyze CH50 and immunoglobulins G (IgG) subclasses production in aGHD, comparing this condition to healthy controls. 38 subjects were included and divided as follows: aGHD (n = 18, 6 females and 12 males); healthy controls (n = 20, 10 females and 10 males).
Why It Was Studied
CH50 is a screening assay for the activation of the classical complement pathway, the immunoglobulins-mediated one, activated in several inflammatory diseases.
Adult growth hormone deficiency (aGHD) is recognized as a chronic inflammatory condition, although poorly evaluated under the profile of inflammatory biomarkers.
Who Took Part
According to the abstract, 38 subjects were involved.
PubMed indexes the participants as adults, middle-aged adults and older adults, both men and women.
How the Study Was Run
The two groups were evaluated for hormonal and metabolic parameters, CH50 and IgG subtypes.
What Was Measured
Adult growth hormone deficiency (aGHD) is recognized as a chronic inflammatory condition, although poorly evaluated under the profile of inflammatory biomarkers.
PubMed files the paper under topics including Arginine, Body Mass Index, Case-Control Studies, Complement Hemolytic Activity Assay, Complement System Proteins, Growth Hormone-Releasing Hormone and Human Growth Hormone.
The authors tagged it with the keywords CH50, Free light chains, GHD, Immunoglobulins and Low grade chronic inflammation.
What This Means in Plain Language
This is an observational study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and GHRH (Growth Hormone-Releasing Hormone) in 38 subjects.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The publication is from 2020 (Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie), a journal based in France.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page and the GHRH (Growth Hormone-Releasing Hormone) compound page, all human trials.
Our Notes on the Compounds
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
GHRH (Growth Hormone-Releasing Hormone): The 44-amino-acid hypothalamic hormone that tells the pituitary to release growth hormone; sermorelin and tesamorelin are analogs.
Related Pages
- Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in the library
- GHRH (Growth Hormone-Releasing Hormone) in the library
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.